

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



B42

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A01N 43/16, 43/18, 43/40, A61K 31/35, 31/38, 31/445	A1	(11) International Publication Number: WO 98/03069 (43) International Publication Date: 29 January 1998 (29.01.98)
(21) International Application Number: PCT/US97/12229 (22) International Filing Date: 14 July 1997 (14.07.97) (30) Priority Data: 60/022,866 24 July 1996 (24.07.96) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US). (72) Inventors: GREGG, Richard, E.; 7 Linden Lane, Pennington, NJ 08543 (US). POULEUR, Hubert, G.; 43 Woodlane Road, Lawrenceville, NJ 08648 (US). WETTERAU, John, R., II; 190 Rugby Drive, Langhorne, PA 19047 (US). (74) Agents: RODNEY, Burton et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD FOR LOWERING SERUM LIPID LEVELS EMPLOYING AN MTP INHIBITOR IN COMBINATION WITH ANOTHER CHOLESTEROL LOWERING DRUG (57) Abstract A method is provided for lowering serum lipids, cholesterol and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an MTP inhibitor, in combination with a cholesterol lowering drug, such as pravastatin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NR	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

METHOD FOR LOWERING SERUM LIPID LEVELS
EMPLOYING AN MTP INHIBITOR IN COMBINATION WITH
ANOTHER CHOLESTEROL LOWERING DRUG

5 Field of the Invention

 The present invention relates to a method
for lowering serum lipids, cholesterol and/or
triglycerides in mammalian species by administering
an MTP inhibitor in combination with another
10 cholesterol lowering drug, for example, an HMG CoA
reductase inhibitor, such as pravastatin,
lovastatin or simvastatin.

Background of the Invention

15 The use of microsomal triglyceride transfer
protein (MTP) inhibitors for decreasing serum
lipids including cholesterol and triglycerides and
their use in treating atherosclerosis, obesity and
pancreatitis is disclosed in Canadian Patent
20 Application No. 2,091,102 (corresponding to U.S.
Application Serial No. 117,362), U.S. Application
Serial No. 472,067, filed June 6, 1995 (file
DC2le), U.S. Application Serial No. 548,811 (file
DC2lh), U.S. provisional application No.
25 60/017,224, (file HX79a*), U.S. provisional
application No. 60/017,253, (file HX82*) and U.S.
provisional application No. 60/017,254, (file
HX84*).

 All of the above U.S. applications are
30 incorporated herein by reference.

Description of the Invention

 In accordance with the present invention, a
method for preventing, inhibiting or treating
35 atherosclerosis, pancreatitis or obesity is
provided, wherein an MTP inhibitor in combination

- 2 -

with another cholesterol lowering drug is administered in therapeutically effective amounts to lower LDL cholesterol and triglycerides.

Furthermore, in accordance with the present invention, a method is provided for lowering serum lipid levels, cholesterol and/or triglycerides, or inhibiting and/or treating hyperlipemia, hyperlipid-emia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, wherein a combination of an MTP inhibitor and another cholesterol lowering drug is administered in therapeutically effective amounts.

In addition, in accordance with the present invention, a novel combination of cholesterol lowering agents is provided which includes an MTP inhibitor and another cholesterol lowering drug.

Cholesterol lowering drugs or drugs which are inhibitors of cholesterol biosynthesis which may be used in the method of the invention in combination with the MTP inhibitor include HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, bile acid sequestrants, probucol, niacin, niacin derivatives, neomycin, aspirin, and the like.

It is believed that the combination of MTP inhibitor and other cholesterol lowering drug, which works by a mechanism other than inhibiting MTP, is a surprising and unique concept in treating diseases involved with elevated cholesterol and/or triglycerides and atherosclerosis, obesity and/or pancreatitis, in that the combination may provide additional anticholesterolemic effects over that which may be obtained using each of the components of the combination alone. It is expected that reduced levels of each of the MTP inhibitor and other cholesterol lowering drug may be employed to

- 3 -

achieve desired results, albeit with reduced side effects.

Detailed Description of the Invention

5 The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.

10 The term "MTP" refers to a polypeptide or protein complex that (1) if obtained from an organism (e. g., cows, humans, etc.), can be isolated from the microsomal fraction of homogenized tissue; and (2) stimulates the transport of triglycerides, cholesterol esters, or phospholipids from synthetic phospholipid vesicles, membranes or lipoproteins to synthetic vesicles, membranes, or lipoproteins and which is distinct from the cholesterol ester transfer protein [Drayna et al., Nature 327, 632-634 (1987)] which may have similar catalytic properties.

20 The phrase "stabilizing" atherosclerosis as used in the present application refers to slowing down the development of and/or inhibiting the formation of new atherosclerotic lesions.

25 The phrase "causing the regression of" atherosclerosis as used in the present application refers to reducing and/or eliminating atherosclerotic lesions.

30 The combination of the MTP inhibitor and other cholesterol lowering drug will be employed in a weight ratio to each other of within the range of from about 1000:1 to about 0.001:1 and preferably from about 0.05:1 to about 100:1.


35 MTP inhibitors to be employed in the methods of the invention include MTP inhibitors disclosed in Canadian Patent Application No. 2,091,102 (corresponding to U.S. Application Serial

- 4 -


No. 117,362), U.S. Application Serial No. 472,067, filed June 6, 1995 (file DC2le), U.S. Application Serial No. 548,811 (file DC2lh), U.S. provisional application No. 60/017,224, (file HX79a*), U.S. provisional application No. 60/017,253, (file HX82*) and U.S. provisional application No. 60/017,254, (file HX84*).

All of the above U.S. applications are incorporated herein by reference.


The MTP inhibitors disclosed in U.S. Application Serial No. 472,067, filed June 6, 1995 (file DC2le) are piperidine compounds of the structure




or




or



or



or



where Q is $\text{—}\overset{\text{O}}{\parallel}\text{C—}$ or $\text{—}\overset{\text{O}}{\parallel}\text{S—}$;

- 5 -

X is: CHR^8 , $-\text{C}(=\text{O})-$, $-\text{CH}(\text{R}^9)-\text{CH}(\text{R}^{10})-$ or $-\text{C}(\text{R}^9)=\text{C}(\text{R}^{10})-$;


R^8 , R^9 and R^{10} are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

Y is $-(\text{CH}_2)_m-$ or $-\text{C}(=\text{O})-$


wherein m is 2 or 3;

R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl wherein alkyl has at least 2 carbons, diarylalkyl, arylalkenyl, diarylalkenyl, arylalkynyl, diarylalkynyl, diarylalkylaryl, heteroarylalkyl wherein alkyl has at least 2 carbons, cycloalkyl, or cycloalkylalkyl wherein alkyl has at least 2 carbons, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from halo, haloalkyl, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, fluorenyl, heteroarylalkyl, hydroxy or oxo;




or R^1 is a fluorenyl-type group of the structure




- 6 -



R¹ is an indenyl-type group of the structure



10 Z¹ and Z² are the same or different and are independently a bond, O, S,




15 with the proviso that with respect to B, at least one of Z¹ and Z² will be other than a bond; R¹¹ is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylene-alkylene; R¹² is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, heteroaryl, heteroarylalkyl, arylalkyl, arylalkenyl, cyclo-

- 7 -

alkyl, aryloxy, alkoxy, arylalkoxy or cycloalkyl-alkyl, with the provisos that

(1) when R^{12} is H, aryloxy, alkoxy or arylalkoxy, then Z^2 is




5 or a bond and

(2) when Z^2 is a bond, R^{12} cannot be heteroaryl or heteroarylalkyl;

Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms;
 10 R^{13} , R^{14} , R^{15} , and R^{16} are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl,
 15 alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl or aryloxy;

R^{15a} and R^{16a} are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cyclo-
 20 heteroalkyl, alkenyl, alkynyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonylamino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy;


25 or R^1 is a group of the structure



wherein p is 1 to 8 and R^{17} and R^{18} are each independently H, alkyl, alkenyl, aryl, arylalkyl,
 30 heteroaryl, heteroarylalkyl, cycloalkyl or cycloalkylalkyl at least one of R^{17} and R^{18} being other than H;

or R^1 is a group of the structure

- 8 -



wherein R¹⁹ is aryl or heteroaryl;

R²⁰ is aryl or heteroaryl;

R²¹ is H, alkyl, aryl, alkylaryl, arylalkyl,
 5 aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl,
 heteroarylalkoxy, cycloalkyl, cycloalkylalkyl or
 cycloalkylalkoxy;

R², R³, R⁴ are independently hydrogen,
 halo, alkyl, alkenyl, alkoxy, aryloxy, aryl,
 10 arylalkyl, alkylmercapto, arylmercapto, cycloalkyl,
 cycloalkylalkyl, heteroaryl, heteroarylalkyl,
 hydroxy or haloalkyl;

R⁵ is independently alkyl, alkenyl, alkynyl,
 aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl,
 15 arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkyl-
 alkyl, polycycloalkyl, polycycloalkylalkyl,
 cycloalkenyl, cycloheteroalkyl, heteroaryloxy,
 cycloalkenylalkyl, polycycloalkenyl, polycyclo-
 alkenylalkyl, heteroarylcarbonyl, amino,
 20 alkylamino, arylamino, heteroarylamino,
 cycloalkyloxy, cycloalkylamino, all optionally
 substituted through available carbon atoms with 1,
 2, 3 or 4 groups selected from hydrogen, halo,
 alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl,
 25 alkynyl, cycloalkyl, cycloalkylalkyl,
 cycloheteroalkyl, cycloheteroalkylalkyl, aryl,
 heteroaryl, arylalkyl, arylcyclo-alkyl,
 arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl,
 arylalkoxy, arylazo, heteroaryloxo, hetero-
 30 arylalkyl, heteroarylalkenyl, heteroaryloxy,
 hydroxy, nitro, cyano, amino, substituted amino,
 thiol, alkylthio, arylthio, heteroarylthio,
 arylthioalkyl, alkylcarbonyl, arylcarbonyl,
 arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl,
 35 alkynylaminocarbonyl, alkylaminocarbonyl,


- 9 -

alkenylaminocarbonyl, alkylcarbonyloxy,
 arylcarbonyloxy, alkylcarbonylamino,
 arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl,
 arylsulfonyl, alkylsulfonyl, arylsulfonylamino,
 5 heteroarylcarbonylamino, heteroarylsulfinyl,
 heteroarylthio, heteroarylsulfonyl, alkylsulfinyl;

R^6 is hydrogen or C_1 - C_4 alkyl or C_1 - C_4
 alkenyl; all optionally substituted with 1, 2, 3 or
 4 groups which may independently be any of the
 10 substituents listed in the definition of R^5 set out
 above;

R^7 is alkyl, aryl or arylalkyl wherein alkyl
 by itself or as part of arylalkyl is optionally
 substituted with oxo $\left(\begin{smallmatrix} O \\ || \end{smallmatrix} \right)$;

15




are the same or different and are independently
 selected from heteroaryl containing 5- or 6-ring
 members; and

20 N-oxides thereof; and
 pharmaceutically acceptable salts thereof;
 with the provisos that where in the first
 formula X is CH_2 , and R^2 , R^3 and R^4 are each H,
 then R^1 will be other than 3,3-diphenylpropyl, and
 25 in the fifth formula, where one of R^2 , R^3 and R^4 is
 6-fluoro, and the others are H, R^7 will be other
 than 4-(2-methoxyphenyl).

The MTP inhibitors disclosed in U.S.
 application Serial No. 548,811 filed January 11,
 30 1996 (file DC21h), have the structure

- 10 -




including the piperidine N-oxide thereof or a pharmaceutically acceptable salt thereof, wherein Z is a bond, O or S;

5 X^1 and X^2 are independently selected from H or halo;

x is an integer from 2 to 6;

R^5 is heteroaryl, aryl, heterocycloalkyl or cycloalkyl, each R^5 group being optionally substituted with 1, 2, 3 or 4 substituents which may be the same or different.


The MTP inhibitors disclosed in U.S. provisional application No. 60/017,224, filed May 9, 1996 (file HX79a*) have the structure



including pharmaceutically acceptable salts thereof, wherein q is 0, 1 or 2;



A is (1) a bond;

20 (2) -O- ; or



where R^5 is H or lower alkyl or R^5 together with R^2 forms a carbocyclic or heterocyclic ring system containing 4 to 8 members in the ring.


B is a fluorenyl-type group of the structure:



(the above B is also referred to as a fluorenyl-type ring or moiety); or


5

B is an indenyl-type group of the structure




(a = 2,3 or 4)


or



or



or



(the above B is also referred to as an indenyl-type ring or moiety);

R^x is H, alkyl or aryl;

10

R¹ is alkyl, alkenyl, alkynyl, alkoxy, (alkyl or aryl)₃Si (where each alkyl or aryl group is independent), cycloalkyl, cycloalkenyl, substituted alkylamino, substituted arylalkylamino, aryl, arylalkyl, arylamino, aryloxy, heteroaryl, heteroarylalkyl, heteroarylamino, heteroaryloxy, arylsulfonylamino, heteroarylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, -PO(R¹³)(R¹⁴), (where R¹³ and R¹⁴ are independently alkyl, aryl, alkoxy, aryloxy, heteroaryl, heteroarylalkyl, heteroaryloxy,

15


20

- 12 -

heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl, cycloheteroalkoxy, or cycloheteroalkylalkoxy); R^1 can also be aminocarbonyl (where the amino may optionally be substituted with one or two aryl, alkyl or heteroaryl groups); cyano, 1,1-(alkoxyl or aryloxy)₂alkyl (where the two aryl or alkyl substituents can be independently defined, or linked to one another to form a ring, such as 1,3-dioxane or 1,3-dioxolane, connected to L^1 (or L^2 in the case of R^2) at the 2-position); 1,3-dioxane or 1,3-dioxolane connected to L^1 (or L^2 in the case of R^2) at the 4-position.

The R^1 group may have from one to four substituents, which can be any of the R^3 groups or R^1 groups, and any of the preferred R^1 substituents set out below.

R^1 may be substituted with the following preferred substituents: alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxy carbonylamino, heteroaryloxy carbonylamino, uriedo (where the uriedo nitrogens may be substituted with alkyl, aryl or heteroaryl), heterocyclylcarbonylamino (where the heterocycle is connected to the carbonyl group via a nitrogen or carbon atom), alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,



where J is: CHR^{23} , $\text{—}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{—}$, $\text{—}\underset{\text{R}^{24}}{\text{CH}}\text{—}\underset{\text{R}^{25}}{\text{CH}}\text{—}$ or $\text{—}\underset{\text{R}^{24}}{\text{C}}=\underset{\text{R}^{25}}{\text{C}}\text{—}$;

- 13 -

R²³, R²⁴ and R²⁵ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

R²⁰, R²¹, R²² are independently hydrogen, halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; and these preferred substituents may either be directly attached to R¹, or attached via an alkylene chain at an open position.

R² is the same or different from R¹ and is independently any of the groups set out for R¹, H, polyhaloalkyl (such as CF₃CH₂, CF₃CF₂CH₂ or CF₃) or cycloheteroalkyl, and may be substituted with one to four of any of the groups defined for R³, or any of the substituents preferred for R¹.

L¹ is a linking group containing from 1 to 10 carbons in a linear chain (including alkylene, alkenylene or alkynylene), which may contain, within the linking chain any of the following: one or two alkenes, one or two alkynes, an oxygen, an amino group optionally substituted with alkyl or aryl, an oxo group; and may be substituted with one to five alkyl or halo groups (preferably F).


L² may be the same or different from L¹ and may independently be any of the L¹ groups set out above or a single bond.

R³, R^{3'}, R⁴ and R^{4'} may be the same or different and are independently selected from H, halogen, CF₃, haloalkyl, hydroxy, alkoxy, alkyl, aryl, alkenyl, alkenyloxy, alkynyl, alkynyloxy, alkanoyl, nitro, amino, thiol, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, alkylcarbonylamino, cycloheteroalkyl,

- 14 -







cycloheteroalkylalkyl, cyano, Ar, Ar-alkyl, ArO, Ar-amino, Ar-thio, Ar-sulfinyl, Ar-sulfonyl, Ar-carbonyl, Ar-carbonyloxy or Ar-carbonylamino, wherein Ar is aryl or heteroaryl and Ar may optionally include 1, 2 or 3 additional rings fused to Ar;

R^{3a} and R^{3b} are the same or different and are independently any of the R^3 groups except hydroxy, nitro, amino or thio;



are the same or different and independently represent a 5 or 6 membered heteroaryl ring which may contain 1, 2, 3 or 4 heteroatoms in the ring which are independently N, S or O; and including N-oxides.

X (in the fluorenyl type ring) is a bond, or is one of the following groups:



wherein

Y is O, N-R⁶ or S;

n' is 0, 1 or 2;

R⁶ is H, lower alkyl, aryl, -C(O)-R¹¹ or
5 -C(O)-O-R¹¹;

R⁷ and R⁸ are the same or different and are
independently H, alkyl, aryl, halogen, -O-R¹², or

R⁷ and R⁸ together can be oxygen to form a
ketone;

10 R⁹, R¹⁰, R^{9'} and R^{10'} are the same or
different and are independently H, lower alkyl,
aryl or -O-R¹¹;

R^{9''} and R^{10''} are the same or different and
are independently H, lower alkyl, aryl, halogen or
15 -O-R¹¹;

R¹¹ is alkyl or aryl;

R¹² is H, alkyl or aryl.

The following provisos apply to formula I
compounds:

20 (a) when R¹ is unsubstituted alkyl or
unsubstituted arylalkyl, L¹ cannot contain amino;

(b) when R¹ is alkyl, L¹ cannot contain
amino and oxo in adjacent positions (to form an
amido group);

25 (c) when R²L²A- is H₂N-, R¹L¹ cannot
contain amino;

(d) when R¹ is cyano, L¹ must have more
than 2 carbons;


(e) R¹L¹ must contain at least 3 carbons.

30 With respect to compounds IA and IB, R²L²
cannot have an O or N atom directly attached to
S=(O)_q or CR^x(OH), and for IA, R²L² cannot be H.


With respect to compounds IA and IB, where
R¹ is cycloheteroalkyl, R¹ is exclusive of 1-piper-
35 idinyl, 1-pyrrolidinyl, 1-azetidinyll or 1-(2-oxo-
pyrrolidinyl).

The MTP inhibitors disclosed in U.S. provisional application No. 60/017,253, filed May 10, 1996, (file HX82*) are pyrrolidine compounds and have the structure

5 I



II



10

where Q is $\text{—}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{—}$ or $\text{—}\overset{\text{O}}{\underset{\text{O}}{\text{S}}}\text{—}$;

W is H, H or O;

X is: CHR^8 , $\text{—}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{—}$, $\text{—}\underset{\text{R}^9}{\text{CH}}\text{—}\underset{\text{R}^{10}}{\text{CH}}\text{—}$ or $\text{—}\underset{\text{R}^9}{\text{C}}=\underset{\text{R}^{10}}{\text{C}}\text{—}$;


R^8 , R^9 and R^{10} are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

R^1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl (wherein alkyl preferably has at least 2 carbons, more preferably at least 3 carbons), diarylalkyl, arylalkenyl, diarylalkenyl, arylalkynyl, diarylalkynyl, diarylalkylaryl, heteroarylalkyl (wherein alkyl preferably has at least 2 carbons, more preferably at least 3 carbons), cycloalkyl, or cycloalkylalkyl (wherein alkyl preferably has at least 2 carbons, more preferably at least 3 carbons); all of the aforementioned R^1 groups being optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from halo, haloalkyl, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl,

- 17 -


alkyl-mercapto, arylmercapto, cycloalkyl,
cycloalkylalkyl, heteroaryl, fluorenyl,
heteroarylalkyl, hydroxy or oxo; or

R^1 is a fluorenyl-type group of the
5 structure



10


R^1 is an indenyl-type group of the structure



E

(a = 2,3 or 4)

E




15

G

H

Z^1 and Z^2 are the same or different and are
independently a bond, O, S,

- 18 -




with the proviso that with respect to B, at least one of Z¹ and Z² will be other than a bond;

- R¹¹ is a bond, alkylene, alkenylene or
 5 alkynylene of up to 10 carbon atoms, arylene (for example



or mixed arylene-alkylene (for example



- 10 where n is 1 to 6;

- R¹² is hydrogen, alkyl, alkenyl, aryl, halo-alkyl, trihaloalkyl, trihaloalkylalkyl, heteroaryl, heteroarylalkyl, arylalkyl, arylalkenyl, cyclo-alkyl, aryloxy, alkoxy, arylalkoxy or cycloalkyl-
 15 alkyl; with the provisos that (1) when R¹² is H, arylalkoxy, alkoxy or arylalkoxy, then Z² is
- $$-\text{NH}-\begin{array}{c} \text{C} \\ \parallel \\ \text{O} \end{array}-, \quad -\underset{\text{alkyl}}{\text{N}}-\begin{array}{c} \text{C} \\ \parallel \\ \text{O} \end{array}-, \quad -\begin{array}{c} \text{C} \\ \parallel \\ \text{O} \end{array}- \quad \text{or a bond;}$$


and (2) when Z² is a bond, R¹² cannot be heteroaryl or heteroarylalkyl;

- 20 Z is a bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene of from 1 to 5 carbon atoms;


- R¹³, R¹⁴, R¹⁵, and R¹⁶ are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy,
 25 alkoxy, nitro, amino, thio, alkylsulfonyl, arylsulfonyl, alkylthio, arylthio, aminocarbonyl, alkylcarbonyloxy, arylcarbonylamino, alkylcarbonyl-amino, arylalkyl, heteroaryl, heteroarylalkyl, or aryloxy;

- 30 R^{15a} and R^{16a} are independently any of the R¹⁵ or R¹⁶ groups except hydroxy, nitro, amino or thio;

- 19 -


or R¹ is

wherein p is 1 to 8 and R¹⁷ and R¹⁸ are each
independently H, alkyl, alkenyl, aryl, arylalkyl,
5 heteroaryl, heteroarylalkyl, cycloalkyl or
cycloalkylalkyl, at least one of R¹⁷ and R¹⁸ being
other than H;

or R¹ is

- 10 wherein R¹⁹ is aryl or heteroaryl;
R²⁰ is aryl or heteroaryl;
R²¹ is H, alkyl, aryl, alkylaryl, arylalkyl,
aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl,
heteroarylalkoxy, cycloalkyl, cycloalkylalkyl or
15 cycloalkylalkoxy;
R², R³, R⁴ are independently hydrogen, halo,
alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl,
alkylmercapto, arylmercapto, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroarylalkyl,
20 hydroxy or haloalkyl;
R⁵ is alkyl, alkenyl, alkynyl, aryl,
alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl,
heteroarylalkyl, cycloalkyl, cycloheteroalkyl,
heteroaryloxy, cycloalkylalkyl, polycycloalkyl,
25 polycycloalkylalkyl, cycloalkenyl, cycloalkenyl-
alkyl, polycycloalkenyl, polycycloalkenylalkyl,
heteroarylcarbonyl, amino, alkylamino, arylamino,
heteroarylamino, cycloalkyloxy, cycloalkylamino,
all of the R⁵ substituents and R⁶ substituents (set
30 out hereinafter) being optionally substituted
through available carbon atoms with 1, 2, 3 or 4
groups selected from hydrogen, halo, alkyl,
haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl,
cycloalkyl, cycloalkylalkyl, cycloheteroalkyl,


- cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy,
- 5 hydroxy, nitro, cyano, amino, substituted amino (wherein the amino includes 1 or 2 substituents which are alkyl, aryl or heteroaryl, or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio,
- 10 arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino,
- 15 arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl. Where R^5 is phenyl, aryl,
- 20 heteroaryl or cycloalkyl; this group preferably includes an ortho hydrophobic substituent such as alkyl, haloalkyl (with up to 5 halo groups), alkoxy, haloalkoxy (with up to 5 halo groups), aryl, aryloxy or arylalkyl;
- 25 R^6 is hydrogen or C_1 - C_4 alkyl or C_1 - C_4 alkenyl;



- are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and
- 30

including N-oxides of the formulae I and II compounds, that is


- 21 -




including pharmaceutically acceptable salts thereof.

The MTP inhibitors disclosed in U.S. provisional application No. 60/017,254, filed May 10, 1996, (file HX84*) are azetidine compounds which have the structure

I



10 II



where Q is $\text{--}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{--}$ or $\text{--}\overset{\text{O}}{\underset{\text{O}}{\text{S}}}\text{--}$;

X is: CHR^8 , $\text{--}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{--}$, $\text{--}\underset{\text{R}^9}{\text{CH}}\text{--}\underset{\text{R}^{10}}{\text{CH}}\text{--}$ or $\text{--}\underset{\text{R}^9}{\text{C}}=\underset{\text{R}^{10}}{\text{C}}\text{--}$; n is 0 or 1;

R^8 , R^9 and R^{10} are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

R^1 is alkyl, alkenyl, alkynyl, aryl,



heteroaryl, arylalkyl (wherein alkyl preferably has at least 2 carbons, more preferably at least 3 carbons), diarylalkyl, arylalkenyl, diarylalkenyl, arylalkynyl, diarylalkynyl, diarylalkylaryl, heteroarylalkyl (wherein alkyl preferably has at least 2 carbons, more preferably at least 3 carbons), cycloalkyl, or cycloalkylalkyl (wherein alkyl preferably has at least 2 carbons, more preferably at least 3 carbons); all of the

- 22 -

aforementioned R^1 groups being optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from halo, haloalkyl, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, fluorenyl, heteroaryl-alkyl, hydroxy or oxo; or


R^1 is a fluorenyl-type group of the structure


10




15

R^1 is an indenyl-type group of the structure






Z^1 and Z^2 are the same or different and are independently a bond, O, S,




with the proviso that with respect to **E**, at least one of Z^1 and Z^2 will be other than a bond;

R^{11} is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms, arylene (for example




or mixed arylene-alkylene (for example



where q is 1 to 6;

R^{12} is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, heteroaryl, heteroarylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl; with the provisos that (1) when R^{12} is H, aryloxy, alkoxy or arylalkoxy, then Z^2 is



and (2) when Z^2 is a bond, R^{12} cannot be heteroaryl or heteroarylalkyl;

Z is a bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene of from 1 to 5 carbon atoms;


R^{13} , R^{14} , R^{15} , and R^{16} are independently hydrogen, alkyl, halo, haloalkyl, aryl, cycloalkyl, cycloheteroalkyl, alkenyl, alkynyl, hydroxy,

alkoxy, nitro, amino, thio, alkylsulfonyl,
 arylsulfonyl, alkylthio, arylthio, aminocarbonyl,
 alkylcarbonyloxy, arylcarbonylamino,
 alkylcarbonylamino, arylalkyl, heteroaryl,

5 heteroarylalkyl, or aryloxy;

R^{15a} and R^{16a} are independently any of the
 R¹⁵ or R¹⁶ groups except hydroxy, nitro, amino or
 thio;

or R¹ is




10

wherein p is 1 to 8 and R¹⁷ and R¹⁸ are each
 independently H, alkyl, alkenyl, aryl, arylalkyl,
 heteroaryl, heteroarylalkyl, cycloalkyl or
 cycloalkylalkyl, at least one of R¹⁷ and R¹⁸ being

15 other than H;

or R¹ is



wherein R¹⁹ is aryl or heteroaryl;

R²⁰ is aryl or heteroaryl;

20 R²¹ is H, alkyl, aryl, alkylaryl, arylalkyl,
 aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl,
 heteroarylalkoxy, cycloalkyl, cycloalkylalkyl or
 cycloalkylalkoxy;


R², R³, R⁴ are independently hydrogen, halo,
 25 alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl,
 alkylmercapto, arylmercapto, cycloalkyl,
 cycloalkylalkyl, heteroaryl, heteroarylalkyl,
 hydroxy or haloalkyl;

R⁵ is alkyl, alkenyl, alkynyl, aryl,
 30 alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl,
 heteroarylalkyl, cycloalkyl, cycloheteroalkyl,
 heteroaryloxy, cycloalkylalkyl, polycycloalkyl,
 polycycloalkylalkyl, cycloalkenyl,
 cycloalkenylalkyl, polycycloalkenyl,

- 25 -


- polycycloalkenylalkyl, heteroarylcarbonyl, amino, alkylamino, arylamino, heteroarylamino, cycloalkyloxy, cycloalkylamino, all of the R⁵ substituents and R⁶ substituents (set out
- 5 hereinafter) being optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl,
- 10 cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxy, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino
- 15 (wherein the amino includes 1 or 2 substituents which are alkyl, aryl or heteroaryl, or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl,
- 20 arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl,
- 25 arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, or alkylsulfinyl. Where R⁵ is phenyl, aryl, heteroaryl or cycloalkyl; this group preferably
- 30 includes an ortho hydrophobic substituent such as alkyl, haloalkyl (with up to 5 halo groups), alkoxy, haloalkoxy (with up to 5 halo groups), aryl, aryloxy or arylalkyl;
- 35 R⁶ is hydrogen or C₁-C₄ alkyl or C₁-C₄ alkenyl;

- 26 -



are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and

- 5 including N-oxides of the formulae I and II compounds, that is



including pharmaceutically acceptable salts thereof.

- 10 Compounds disclosed as preferred in each of the above applications are preferred for use in the present invention.


- Most preferred MTP inhibitors to be employed in accordance with the present invention include preferred MTP inhibitors as set out in U.S. patent application Serial No. 548,811, filed January 11, 1996 (file DC21h) and in U.S. provisional application No. 60/017,224, filed May 9, 1996 (file HX79a*).

- 20 Thus, preferred compounds in U.S. patent application Serial No. 548,811 (file DC21h) for use herein are compounds

where Z is a bond;


X¹ and X² are H;

- 25 R⁵ is aryl such as phenyl substituted with



- 27 -

(2) heteroaryl such as




(3) halo such as Cl

R⁵ is heteroaryl such as


substituted with




5 (1) aroyl such as



(2) arylthio such as




wherein the R⁵ substituent is preferably in the position adjacent to the carbon linked to $\overset{\text{O}}{\parallel}{\text{C}}$.

(CH₂)_x is -(CH₂)₄- or

10

Most preferred is


9-[4-{4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide



15


Preferred compounds in U.S. provisional application No. 60/017,224 (file HX79a*) for use herein are MTP inhibitor compounds of formula I that is

- 28 -



wherein A is NH,

B is



5 X is a bond, oxygen or sulfur; R^3 and R^4 are independently H or F.

Preferred R^1 groups are aryl, preferably phenyl, heteroaryl, preferably imidazolyl or pyridyl (preferably substituted with one of the preferred
 10 R^1 substituents: arylcarbonylamino, heteroarylcarbonylamino, cycloalkylcarbonylamino, alkoxy carbonylamino, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino), $PO(OAlkyl)_2$, heteroarylthio, benzthi-azole-2-thio,
 15 imidazole-2-thio, alkyl, or alkenyl, cycloalkyl such as cyclohexyl, or 1,3-dioxan-2-yl.

Preferred R^2 groups are alkyl, polyfluoroalkyl (such as 1,1,1-trifluoroethyl), alkenyl, aryl or heteroaryl (preferably substituted
 20 with one of the preferred R^1 substituents above), or $PO(OAlkyl)_2$.

If R^2 is alkyl, 1,1,1-trifluoroethyl, or alkenyl, it is preferred that R^1 is other than alkyl or alkenyl.

25 It is preferred that L^1 contains 1 to 5 atoms in the linear chain and L^2 is a bond or lower alkylene.

Preferred embodiments of formula IA and formula IB compounds of the invention include those
 30 where B, L^1 , L^2 , R^1 and R^2 are as set out with respect to the preferred embodiments of the formula I compounds, q is 0 or 2 and R^x is H.

- 29 -


The other cholesterol lowering drug to be used in combination with the MTP inhibitor in accordance with the present invention is preferably an HMG CoA reductase inhibitor.

- 5 The HMG CoA reductase inhibitors suitable for use herein include, but are not limited to, mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Patent
10 No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171, with pravastatin, lovastatin or simvastatin being
15 preferred. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to, fluvastatin, cerivastatin, atorvastatin, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Patent No.
20 4,613,610, indene analogs of mevalonolactone derivatives as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-ones and derivatives thereof as disclosed in U.S. Patent No. 4,647,576, Searle's
25 SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed in French Patent No.
30 2,596,393, 2,3-di-substituted pyrrole, furan and thiophene derivatives as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Patent No. 4,686,237, octahydro-naphthalenes such as disclosed
35 in U.S. Patent No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European

Patent Application No. 0,142,146 A2, as well as other known HMG CoA reductase inhibitors.


In addition, phosphinic acid compounds useful in inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.

The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphonosulfonates disclosed in U.S. application Serial No. 08/266,888, filed July 5, 1994 (HX59b), those disclosed by Biller et al, J. Med. Chem. 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinylmethyl)phosphonates such as those of the formula



I

II

R¹

including the triacids thereof, triesters thereof and tripotassium and trisodium salts thereof as well as other squalene synthetase inhibitors

- 31 -

disclosed in U.S. Patent Nos. 4,871,721 and 4,924,024 and in Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869 to 1871.

In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem.; 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc. 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract, Table of Contents, pp. 16, 17, 40-43, 48-51, Summary.

Preferred are pravastatin, lovastatin or simvastatin.

All of the above U.S. applications are incorporated herein by reference.

Other cholesterol lowering drugs suitable for use herein include, but are not limited to, antihyperlipoproteinemic agents such as fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex[®], Polidexide[®]), as well as clofibrate, lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo),

- 32 -

Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives
5 such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.

10 In carrying out the method of the present invention, the MTP inhibitor in combination with the cholesterol lowering drug may be administered to mammalian species, such as monkeys, dogs, cats, rats, humans, etc., and, as such, may be
15 incorporated in a conventional systemic dosage form, such as a tablet, capsule, elixir or injectable. The above dosage forms will also include the necessary carrier material, excipient, lubricant, buffer, antibacterial, bulking agent
20 (such as mennitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms are preferred, although parenteral forms are quite satisfactory as well.

The dose administered must be carefully
25 adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.

For oral administration, a satisfactory
30 result may be obtained employing the MTP inhibitor in an amount within the range of from about 0.01 mg/kg to about 100 mg/kg and preferably from about 0.1 mg/kg to about 75 mg/kg.

A preferred oral dosage form, such as
35 tablets or capsules, will contain the MTP inhibitor in an amount of from about 5 to about 500 mg,

- 33 -

preferably from about 10 to about 400 mg, and more preferably from about 20 to about 250 mg.

For parenteral administration, the MTP inhibitor will be employed in an amount within the
5 range of from about 0.005 mg/kg to about 10 mg/kg and preferably from about 0.005 mg/kg to about 8 mg/kg.

For oral administration, a satisfactory result may be obtained employing the HMG CoA
10 reductase inhibitor in dosages employed, for example, for pravastatin, simvastatin, fluvastatin and lovastatin, as indicated in the Physician's Desk Reference, such as in an amount within the range of from about 1 to 2000 mg, and preferably
15 from about 4 to about 200 mg. The squalene synthetase inhibitor may be employed in dosages in an amount within the range of from about 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

A preferred oral dosage form, such as
20 tablets or capsules, will contain MTP inhibitor in an amount of from about 10 to about 400 mg, and the HMG CoA reductase inhibitor in an amount of from about 0.1 to about 100 mg, preferably from about 5
25 to about 80 mg, and more preferably from about 10 to about 50 mg.

The other serum cholesterol lowering drugs when present will be employed in dosages normally employed as indicated in the Physician's Desk
30 Reference, for each of such agents such as in an amount within the range of from about 2 mg to about 7500 mg and preferably from about 2 mg to about 4000 mg.

The MTP inhibitor and other cholesterol
35 lowering agent may be employed together in the same

- 34 -

oral dosage form or in separate oral dosage forms taken at the same time.

The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination.

Tablets of various sizes can be prepared, e.g., of about 2 to 2000 mg in total weight, containing one or both of the active substances in the ranges described above, with the remainder being a physiologically acceptable carrier of other materials according to accepted pharmaceutical practice. These tablets can, of course, be scored to provide for fractional doses. Gelatin capsules can be similarly formulated.

Liquid formulations can also be prepared by dissolving or suspending one or the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsful.

Such dosage forms can be administered to the patient on a regimen of one to four doses per day.

According to another modification, in order to more finely regulate the dosage schedule, the active substances may be administered separately in individual dosage units at the same time or carefully coordinated times. Since blood levels are built up and maintained by a regulated schedule of administration, the same result is achieved by the simultaneous presence of the two substances. The respective substances can be individually

- 35 -

formulated in separate unit dosage forms in a manner similar to that described above.

Fixed combinations of MTP inhibitor and other cholesterol lowering drug are more convenient and are preferred, especially in tablet or capsule form for oral administration.

In formulating the compositions, the active substances, in the amounts described above, are compounded according to accepted pharmaceutical practice with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in the particular type of unit dosage form.

Illustrative of the adjuvants which may be incorporated in tablets are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate or cellulose; a disintegrating agent such as corn starch, potato starch, alginic acid or the like; a lubricant such as stearic acid or magnesium stearate; a sweetening agent such as sucrose, aspartame, lactose or saccharin; a flavoring agent such as orange, peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets or capsules may be coated with shellac, sugar or both. A syrup of elixir may contain the active compound, water, alcohol or the like as the carrier, glycerol as solubilizer, sucrose as sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange.

Some of the active substances described above form commonly known, pharmaceutically acceptable salts such as alkali metal and other common basic salts or acid addition salts, etc. References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent compound.

The formulations as described above will be administered for a prolonged period, that is, for as long as the potential for elevated cholesterol and/or triglycerides and/or atherosclerosis and other diseases set out above remains or the symptoms continue. Sustained release forms of such formulations which may provide such amounts biweekly, weekly, monthly and the like may also be employed. A dosing period of at least one to two weeks are required to achieve minimal benefit.

The following Examples represent preferred embodiments of the present invention.

20

Examples 1 and 2

Formulations suitable for oral administration for reducing serum cholesterol are prepared as described below.

25

Capsules each containing about 5 mg MTP inhibitor BMS 201,038 (Example 1) and capsules each containing about 50 mg BMS 201,038 (Example 2) are produced from the following ingredients.

- 37 -

5	<u>Ingredient</u>	Example 1	Example 2
		<u>Amount (mg/ Capsule)</u>	<u>Amount (mg/ Capsule)</u>
	BMS-201038-methane sulfonic acid salt (1)	5.7	56.9
	Lactose, Hydrous, NF	ca. 151.1	ca. 99.9
	Microcrystalline Cellulose, NF	50.0	50.0
	Pregelatinized Starch, NF	25.0	25.0
	Sodium Starch Glycolate, NF	12.5	12.5
	Colloidal Silicon Dioxide, NF	5.0	5.0
	Magnesium Stearate, NF	0.6	0.6
	Purified Water, USP or	q.s.	q.s.
	Water for Injection, USP	q.s.	q.s.
	Gray, Opaque, Size #0 Capsule Shell	One Capsule	One Capsule
		about	about
	Total Fill Weight	250.0	250.0

(1) This amount is expressed in terms of the amount of methane sulfonic acid salt per capsule at 100% potency. This is equivalent to 5 mg and 50 mg (Examples 1 and 2, respectively) of the free base.

10

The MTP inhibitor BMS 201,038, and colloidal silicon dioxide are blended in a suitable blender with lactose hydrous, microcrystalline cellulose, pregelatinized starch and a portion of sodium starch glycolate. The resulting blend is wet granulated with water. The wet granulation is dried in a suitable dryer. The remaining portion of sodium starch glycolate is added to the granulation and mixed therein. Magnesium stearate is added to

15

- 38 -

the granulation and mixed therein. The resulting blend is filled into capsules.

Example 3

5 Pravastatin tablets (10, 20 or 40 mg as described in the 1996 PDR) and MTP inhibitor (BMS 201,238) tablets may be administered as a combination in accordance with the teachings of the present invention to lower serum cholesterol. In
10 addition, the pravastatin and MTP inhibitor tablets may be ground up into powders and used together in a single capsule.

Example 4

15 Tablets containing 500 mg clofibrate by itself or in combination with 10 mg BMS 201,038 may be employed in separate dosage forms or combined in a single capsule form to lower serum cholesterol in accordance with the present invention.

20

Examples 5, 6 and 7


Ciprofibrate, bezafibrate, gemfibrozil alone or in combination with an MTP inhibitor may also be prepared in a manner described hereinbefore
25 in Examples 1 to 3 for use in lowering serum cholesterol.

- 39 -


What is claimed is:

1. A pharmaceutical combination comprising an MTP inhibitor and another cholesterol lowering agent.

2. The combination as defined in Claim 1 wherein the MTP inhibitor has the structure




or




10

or




or



15

or



where Q is $\text{--}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{--}$ or $\text{--}\overset{\text{O}}{\underset{\text{O}}{\text{S}}}\text{--}$;

X is: CHR^8 , $\text{--}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}\text{--}$, $\text{--}\underset{\text{R}^9}{\text{CH}}\text{--}\underset{\text{R}^{10}}{\text{CH}}\text{--}$ or $\text{--}\underset{\text{R}^9}{\text{C}}\text{=}\underset{\text{R}^{10}}{\text{C}}\text{--}$;

20

R^8 , R^9 and R^{10} are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;


- 40 -

Y is $-(CH_2)_m-$ or $-\overset{\overset{O}{\parallel}}{C}-$

wherein m is 2 or 3;

R¹ is alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl wherein alkyl has at least 2
 5 carbons, diarylalkyl, arylalkenyl, diarylalkenyl, arylalkynyl, diarylalkynyl, diarylalkylaryl, heteroarylalkyl wherein alkyl has at least 2 carbons, cycloalkyl, or cycloalkylalkyl wherein alkyl has at least 2 carbons, all optionally
 10 substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from halo, haloalkyl, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, fluorenyl, heteroarylalkyl,
 15 hydroxy or oxo;


or R¹ is a fluorenyl-type group of the structure




R¹ is an indenyl-type group of the structure

25

- 41 -




5 Z^1 and Z^2 are the same or different and are independently a bond, O, S,



10 with the proviso that with respect to B, at least one of Z^1 and Z^2 will be other than a bond; R^{11} is a bond, alkylene, alkenylene or alkynylene of up to 10 carbon atoms; arylene or mixed arylene-alkylene; R^{12} is hydrogen, alkyl, alkenyl, aryl, haloalkyl, trihaloalkyl, trihaloalkylalkyl, heteroaryl, 15 heteroarylalkyl, arylalkyl, arylalkenyl, cycloalkyl, aryloxy, alkoxy, arylalkoxy or cycloalkylalkyl, with the provisos that

(1) when R^{12} is H, aryloxy, alkoxy or arylalkoxy, then Z^2 is



20 or a bond and

(2) when Z^2 is a bond, R^{12} cannot be heteroaryl or heteroarylalkyl;


Z is bond, O, S, N-alkyl, N-aryl, or alkylene or alkenylene from 1 to 5 carbon atoms;

25 R^{13} , R^{14} , R^{15} , and R^{16} are independently hydrogen,

alkyl, halo, haloalkyl, aryl, cycloalkyl, cyclo-
heteroalkyl, alkenyl, alkynyl, hydroxy, alkoxy,
nitro, amino, thio, alkylsulfonyl, arylsulfonyl,
alkylthio, arylthio, aminocarbonyl,
5 alkylcarbonyloxy, arylcarbonylamino,
alkylcarbonylamino, arylalkyl, heteroaryl,
heteroarylalkyl or aryloxy;


R^{15a} and R^{16a} are independently hydrogen,
alkyl, halo, haloalkyl, aryl, cycloalkyl, cyclo-
10 heteroalkyl, alkenyl, alkynyl, alkoxy, alkyl-
sulfonyl, arylsulfonyl, alkylthio, arylthio, amino-
carbonyl, alkylcarbonyloxy, arylcarbonylamino,
alkylcarbonylamino, arylalkyl, heteroaryl,
heteroarylalkyl, or aryloxy;

15 or R^1 is a group of the structure



wherein p is 1 to 8 and R^{17} and R^{18} are each
independently H, alkyl, alkenyl, aryl, arylalkyl,
20 heteroaryl, heteroarylalkyl, cycloalkyl or
cycloalkylalkyl at least one of R^{17} and R^{18} being
other than H;

or R^1 is a group of the structure



25 wherein R^{19} is aryl or heteroaryl;
 R^{20} is aryl or heteroaryl;
 R^{21} is H, alkyl, aryl, alkylaryl, arylalkyl,
aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl,
30 heteroarylalkoxy, cycloalkyl, cycloalkylalkyl or
cycloalkylalkoxy;

R^2 , R^3 , R^4 are independently hydrogen,
halo, alkyl, alkenyl, alkoxy, aryloxy, aryl,
arylalkyl, alkylmercapto, arylmercapto, cycloalkyl,

- 43 -


cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl;

- R⁵ is independently alkyl, alkenyl, alkynyl, aryl, alkoxy, aryloxy, arylalkoxy, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkyl-alkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloheteroalkyl, heteroaryloxy, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, heteroarylcarbonyl, amino, alkylamino, arylamino, heteroarylamino, cycloalkyloxy, cycloalkylamino, all optionally substituted through available carbon atoms with 1, 2, 3 or 4 groups selected from hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, alkylsulfinyl;


- R⁶ is hydrogen or C₁-C₄ alkyl or C₁-C₄ alkenyl; all optionally substituted with 1, 2, 3 or 4 groups which may independently be any of the substituents listed in the definition of R⁵ set out above;

- 44 -

R⁷ is alkyl, aryl or arylalkyl wherein alkyl by itself or as part of arylalkyl is optionally substituted with oxo $\left(\begin{smallmatrix} \text{O} \\ || \end{smallmatrix} \right)$;




are the same or different and are independently selected from heteroaryl containing 5- or 6-ring members; and



N-oxides thereof; and


10 pharmaceutically acceptable salts thereof; with the provisos that where in the first formula X is CH₂, and R², R³ and R⁴ are each H, then R¹ will be other than 3,3-diphenylpropyl, and in the fifth formula, where one of R², R³ and R⁴ is 15 6-fluoro, and the others are H, R⁷ will be other than 4-(2-methoxyphenyl).

3. The combination as defined in Claim 1 wherein the MTP inhibitor has the formula




4. The combination as defined in Claim 2 where in the MTP inhibitor R¹ is

- 45 -



- 5 5. The combination as defined in Claim 1
 wherein the MTP inhibitor has the structure



- including the piperidine N-oxide thereof or a
 10 pharmaceutically acceptable salt thereof, wherein Z
 is a bond, O or S;

X¹ and X² are independently selected from H
 or halo;



x is an integer from 2 to 6;

- 15 R⁵ is heteroaryl, aryl, heterocycloalkyl or
 cycloalkyl, each R⁵ group being optionally
 substituted with 1, 2, 3 or 4 substituents which
 may be the same or different.


- 46 -

6. The combination as defined in Claim 2 where in the MTP inhibitor R^5 is substituted with 1, 2, 3 or 4 of one or more of the following
I, Cl, F, CF_3


5




10




alkyl, phenyl, phenyl substituted with halo, alkyl,


CF_3O , alkoxy, , CF_3 , or phenyl;

15 $-N-(CH_2)_pCF_3-$ where p is 1 to 5, $-N(CH_3)C_6H_5$;

$-S-(CH_2)_pCF_3$ where p is 1 to 5, , $-S-$ alkyl,


$-S-(CH_2)_p-SO_2-C_6H_5$, $-O-(CH_2)_p-CF_3$, , OCH_3 ;

- 47 -




7. The combination as defined in Claim 2
- 10 where in the MTP inhibitor R⁵ is phenyl substituted with haloalkylphenyl or heteroaryl.

8. The combination as defined in Claim 7
- where in the MTP inhibitor R⁵ is




15


9. The combination as defined in Claim 2
- where in the MTP inhibitor is



or



10. The combination as defined in Claim 2
 5 wherein the MTP inhibitor has the structure



including pharmaceutically acceptable salts thereof, N-oxides thereof,

- 10 wherein q is 0, 1 or 2;

A is (1) a bond;


(2) -O-; or

(3)
$$\begin{array}{c} \text{---} \text{N} \text{---} \\ | \\ \text{R}^5 \end{array}$$



- 15 where R⁵ is H or lower alkyl, or R⁵ together with R² forms a carbocyclic or heterocyclic ring system containing 4 to 8 members in the ring;

B is a fluorenyl-type group of the structure

- 49 -



5 B is an indenyl-type group of the structure




10

R^x is H, alkyl or aryl;

R^1 is alkyl, alkenyl, alkynyl, alkoxy,
(alkyl or aryl)₃Si (where each alkyl or aryl group
is independent), cycloalkyl, cycloalkenyl,

15 substituted alkylamino, substituted arylalkylamino,
aryl, arylalkyl, arylamino, aryloxy, heteroaryl,
heteroarylamino, heteroaryloxy, arylsulfonylamino,
heteroarylsulfonylamino, arylthio, arylsulfinyl,
arylsulfonyl, alkylthio, alkylsulfinyl, alkylsul-
20 fonyl, heteroarylthio, heteroarylsulfinyl, hetero-

- arylsulfonyl, $-\text{PO}(\text{R}^{13})(\text{R}^{14})$, (where R^{13} and R^{14} are independently alkyl, aryl, alkoxy, aryloxy, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylalkoxy, cycloheteroalkyl, cycloheteroalkylalkyl, cycloheteroalkoxy, or cycloheteroalkylalkoxy);
- 5 aminocarbonyl (where the amino may optionally be substituted with one or two aryl, alkyl or heteroaryl groups); cyano, 1,1-(alkoxyl or aryloxy)₂alkyl (where the two aryl or alkyl
- 10 substituents can be independently defined, or linked to one another to form a ring connected to L^1 (or L^2 in the case of R^2) at the 2-position); 1,3-dioxane or 1,3-dioxolane connected to L^1 (or L^2 in the case of R^2) at the 4-position; the R^1 group
- 15 may optionally be substituted with 1, 2, 3 or 4 substituents, which can be any of the R^3 or R^1 groups or alkylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxy carbonylamino, aryloxy carbonylamino,
- 20 heteroaryloxy carbonylamino, uriedo (where the uriedo nitrogens may optionally be substituted with alkyl, aryl or heteroaryl), heterocyclylcarbonylamino (where the heterocycle is connected to the carbonyl group via a nitrogen or carbon atom),
- 25 alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,



- 30 where J is: CHR^{23} , $-\text{C}(=\text{O})-$, $-\text{CH}(\text{R}^{24})-\text{CH}(\text{R}^{25})-$ or $-\text{C}(\text{R}^{24})=\text{C}(\text{R}^{25})-$;

R^{23} , R^{24} and R^{25} are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, or cycloalkylalkyl;

- 51 -

R²⁰, R²¹, R²² are independently hydrogen, halo, alkyl, alkenyl, alkoxy, aryloxy, aryl, arylalkyl, alkylmercapto, arylmercapto, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, hydroxy or haloalkyl; and these substituents may either be directly attached to R¹, or attached via an alkylene at an open position;

R² is independently any of the groups set out for R¹, H, polyhaloalkyl, or cycloheteroalkyl, and may be optionally substituted with one to four of any of the groups defined for R³ or substituents defined for R¹;


L¹ is a linking group containing from 1 to 10 carbons in a linear chain including alkylene, alkenylene or alkynylene, which may contain, within the linking chain any of the following: one or two alkenes, one or two alkynes, an oxygen, an amino group, an oxo group, and may be substituted with one to five alkyl or halo groups;

L² may be the same or different from L¹ and may independently be any of the L¹ groups set out above or a single bond;

R³, R^{3'}, R⁴ and R^{4'} may be the same or different and are independently selected from H, halogen, CF₃, haloalkyl, hydroxy, alkoxy, alkyl, aryl, alkenyl, alkenyloxy, alkynyl, alkynyloxy, alkanoyl, nitro, amino, thiol, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxy, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, alkylcarbonyl-amino, cycloheteroalkyl, cycloheteroalkylalkyl, cyano, Ar-, Ar-alkyl, ArO, Ar-amino, Ar-thio, Ar-sulfinyl, Ar-sulfonyl, Ar-carbonyl, Ar-carbonyloxy or Ar-carbonylamino, wherein Ar is aryl or heteroaryl and Ar may optionally include 1, 2 or 3 additional rings fused to Ar;

- 52 -

R^{3a} and R^{3b} are the same or different and are independently any of the R^3 groups except hydroxy, nitro, amino or thio;



are the same or different and independently represent a 5 or 6 membered heteroaryl ring which contains 1, 2, 3 or 4 heteroatoms in the ring which are independently N, S or O; and including N-oxides;

10 X is a bond, or is one of the following groups:

- (1) ---S---
 $(O)_{n'}$;
- 15 (2) ---O--- ;
- (3) ---N---
 R^6 ;
- (4) ---C---
 $R^7 \quad R^8$;
- 20 (5) ---C---C---
 $R^9 \quad R^{10} R^{9'} \quad R^{10'}$;
- (6) ---C=C---
 $R^{9''} \quad R^{10''}$; or
- 25 (7) ---C---Y---
 $R^9 \quad R^{10}$

wherein

Y is O, N- R^6 or S;

n' is 0, 1 or 2;

R^6 is H, lower alkyl, aryl, $\text{---C(O)---}R^{11}$ or
 30 $\text{---C(O)---O---}R^{11}$;

- 53 -

R^7 and R^8 are the same or different and are independently H, alkyl, aryl, halogen, $-O-R^{12}$, or

R^7 and R^8 together can be oxygen to form a ketone;


5 R^9 , R^{10} , R^9' and $R^{10'}$ are the same or different and are independently H, lower alkyl, aryl or $-O-R^{11}$;

R^9'' and $R^{10''}$ are the same or different and are independently H, lower alkyl, aryl, halogen or
10 $-O-R^{11}$;

R^{11} is alkyl or aryl;

R^{12} is H, alkyl or aryl;

with the following provisos for compound of the



15 (a) when R^1 is unsubstituted alkyl or unsubstituted arylalkyl, L^1 cannot contain amino;

(b) when R^1 is alkyl, L^1 cannot contain amino and oxo in adjacent positions (to form an amido group);

20 (c) when R^2L^2A- is H_2N- , R^1L^1 cannot contain amino;

(d) when R^1 is cyano, L^1 must have more than 2 carbons;


(e) R^1L^1 must contain at least 3 carbons;

25 with respect to compounds of formulas I, IA and IB, where R^1 is cycloheteroalkyl, R^1 is exclusive of 1-piperidinyl, 1-pyrrolidinyl, 1-azetidiny or 1-(2-oxo-pyrrolidinyl);

with respect to the sulfur containing
30 compounds and alcohols, R^2L^2 cannot have an O or N atom directly attached to $S=(O)_q$ or $CR^x(OH)$, and for IA, R^2L^2 cannot be H.


- 54 -

11. The combination as defined in Claim 10 wherein the MTP inhibitor has the structure




12. The combination as defined in Claim 10 where in the MTP inhibitor B is a fluorenyl-type group.

13. The combination as defined in Claim 10 wherein the MTP inhibitor has the formula



10 wherein B is



A is NH;

X is a bond, oxygen or sulfur;

15 R³ and R⁴ are the same or different and are H or F;

20 R¹ is aryl, phenyl, heteroaryl, imidazolyl, pyridyl, cyclohexyl, PO(R¹³)(R¹⁴), heteroarylthio, benzthiazole-2-thio, imidazole-2-thio, alkyl, alkenyl or 1,3-dioxan-2-yl, wherein each of the above is optionally substituted;

R² is alkyl, polyfluoroalkyl, alkenyl, aryl, phenyl, heteroaryl, imidazolyl or pyridyl, wherein each of the above is optionally substituted;

25 L¹ is a chain containing 1 to 5 atoms in a linear chain;

L² is a bond or lower alkylene.

14. The combination as defined in Claim 2 wherein the other cholesterol lowering drug is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase.

30

- 55 -

15. The combination as defined in Claim 2 wherein said inhibitor of the enzyme HMG CoA reductase is lovastatin, pravastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin.

5 16. The combination as defined in Claim 2 wherein the other cholesterol lowering drug is a fibric acid derivative which is gemfibrozil, fenofibrate, clofibrate, bezafibrate, ciprofibrate or clinofibrate, dextrothyroxine or its sodium
10 salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicylic acid or aspirin.

17. The combination as defined in Claim 2 wherein the MTP inhibitor is present in a weight
15 ratio to said cholesterol lowering drug of within the range of from about 0.001:1 to about 1000:1.

18. The combination as defined in Claim 2 wherein the MTP inhibitor is BMS 201,038 and the
20 cholesterol lowering drug is pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin or cerivastatin.

19. A method for preventing, inhibiting or treating atherosclerosis, pancreatitis or obesity in a mammalian species, which comprises
25 administering to a patient in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 1.

20. A method of lowering serum lipid levels, cholesterol and/or triglycerides, or
30 inhibiting and/or treating hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia, and/or preventing, inhibiting or treating atherosclerosis, pancreatitis or obesity, in a
35 mammalian species, which comprises administering to a patient in need of treatment a therapeutically

- 56 -

effective amount of a pharmaceutical combination as defined in Claim 1.

21. The method as defined in Claim 20 wherein the LDL blood level is reduced to at least
5 20% of normal LDL blood level.

22. The method as defined in Claim 20 wherein the LDL blood level is reduced to substantially zero.

10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/12229

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 43/16, 43/18, 43/40; A61K 31/35, 31/38, 31/445

US CL : 514/319, 325, 453, 437, 454

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/319, 325, 453, 437, 454

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Database CA on STN, Schering Corp. USA, WO 9406784, CA No. 121: 133718, Dugar, S., abstract, March 31, 1994.	1-22
A	Database CA on STN, Department of Metabolic Disease, Bristol-Myers Squibb Co., (Princeton, NJ), CA No. 123:191253, Gordon, David et al., "Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles", abstract, Trends Cell Biol., 5(8), 317-321, 1995.	1-22

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
15 SEPTEMBER 1997

Date of mailing of the international search report
15 OCT 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
DWAYNE C. JONES

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/12229

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

CA, CAPLUS, BIOSIS, MEDLINE, EMBASE, REG search terms: structure search with: 3-hydroxy-3-methylglutaryl coenzyme a, hmg coa reductase, hmg-coa reductase, (lovastatin or pravastatin or simvastatin or atorvastatin or fluvastatin or cerivastatin), (fibric acid? or gemfibrozil or fenofibrate or clofibrate or bezafibrate or ciprofibrate or clonofibrate or dextrothyroxine or colestipol or hydrochloride or cholestyramine or nicotinic acid or neomycin or "p-aminosalicylic acid" or aspirin), gregg r?, pouleur h?, welteran j? or wetteran j?, (cholesterol or triglyceride? or serum lipid or hylipidemia)